Search Medical Condition
Please enter condition
Please choose location from dropdown

Anniston, Alabama Clinical Trials

A listing of Anniston, Alabama clinical trials actively recruiting patient volunteers.

RESULTS

Found (21) clinical trials

A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE)

M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study is to assess the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE)

Phase

0.56 miles

Learn More »

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

The primary objective of the study is to evaluate the efficacy of fasinumab compared to placebo, when administered for up to 24 weeks in patients with osteoarthritis (OA) of the knee or hip. The secondary objectives of the study are: to evaluate the efficacy of fasinumab compared to non-steroidal anti-inflammatory ...

Phase

5.3 miles

Learn More »

Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)

This clinical trial is designed as a randomized, placebo-controlled, multi-center phase 2 trial to evaluate the efficacy and safety of OPK-88004 in men with benign prostatic hyperplasia. Eligible subjects will be randomized into one of two OPK-88004 treatment groups or a placebo group after a 4-week screening period. Subjects will ...

Phase

5.3 miles

Learn More »

Safety and Efficacy of AMG 592 in Subjects With Active Rheumatoid Arthritis

Phase 1b. To evaluate the safety and tolerability of subcutaneous (SC)dose administrations of AMG 592 in subjects with active RA. Phase 2a. To evaluate the efficacy of AMG 592 at week 12 as measured by the American College of Rheumatology 20% improvement criteria (ACR 20) in adult subjects with moderate ...

Phase

5.3 miles

Learn More »

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

This study evaluates the efficacy, safety, and tolerability of ustekinumab in participants with active SLE according to Systemic Lupus International Collaborating Clinics (SLICC) criteria Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score greater than (>=) 6, despite receiving one or more standard-of-care treatments (example, immunomodulators, antimalarial drugs, and/or glucocorticoids). ...

Phase

5.3 miles

Learn More »

Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

Ten year safety study examining rates of rare adverse events, child bearing issues, effects of mammography, MRI compliance and results, and long-term benefit of silicone-filled breast implants.

Phase N/A

6.22 miles

Learn More »

Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)

The primary purpose of the study is to evaluate the efficacy of BIIB059 in reducing disease activity in participants with systemic lupus erythematosus (SLE) with active cutaneous manifestations and joint involvement (Part A), and in participants with active cutaneous lupus erythematosus (CLE) (Subacute cutaneous lupus erythematosus (SCLE) or chronic CLE, ...

Phase

7.39 miles

Learn More »

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

The aim of the study is to evaluate efficacy and safety of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with preserved ejection fraction

Phase

7.39 miles

Learn More »

A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease

This is a Phase Ib, randomized, blinded, placebo-controlled, multiple ascendingdose study of the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of BFKB8488A in participants with Type 2 diabetes mellitus (T2DM) and participants with non-alcoholic fatty liver disease(NAFLD). A maximum of approximately 160 participants will be enrolled across multiple sites ...

Phase

7.39 miles

Learn More »

Multiple Ascending Doses of AMG 570 in Subjects With Rheumatoid Arthritis

A study to evaluate the safety and tolerability of AMG 570 following multiple dose administration in subjects with rheumatoid arthritis (RA). A study to characterize the pharmacokinetic profile of AMG 570 following multiple dose administration in subjects with RA. Hypothesis: Multiple dose administration of AMG 570 will have acceptable safety ...

Phase

7.39 miles

Learn More »